MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about newspaper advertisements

10 Aug 2026 Evaluate

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed copies of the newspaper advertisements published on August 09, 2026 in the newspapers: Financial Express (English -New Delhi Edition) and Jansatta (Hindi - New Delhi Edition). The advertisements contain a Quick Response (QR) Code enabling direct access to the unaudited (Standalone & Consolidated) Financial Results of the company for the quarter ended June 30, 2026 as approved by the Board of Directors at its meeting held on August 08, 2026. A copy of this disclosure is being updated on the website of the Company at www.akums.in. 

The above information is a part of company’s filings submitted to BSE. 

Akums Drugs & Pharma Share Price

731.25 34.75 (4.99%)
10-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1952.75
Dr. Reddys Labs. 1157.35
Cipla 1460.00
Lupin 2275.00
Zydus Lifesciences 1120.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: